MindWalk Holdings (HYFT) Capital Expenditures (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Capital Expenditures of $572662.2 for Q2 2026, down 34.23% year-over-year from $870680.8 in Q2 2025, and up 2663.66% quarter-over-quarter from -$22337.7 in Q1 2026.
Powered by 
Analysis
MindWalk Holdings (HYFT) Capital Expenditures (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Capital Expenditures for 4 consecutive years, with $572662.2 the latest figure, recorded in Q2 2026.
- In Q2 2026, Capital Expenditures fell 34.23% year-over-year to $572662.2; the TTM figure through Apr 2026 stood at $291744.1 (down 47.16% YoY), while the FY2026 annual figure was $290343.4, down 49.38% from the prior year.
- Capital Expenditures rose to $572662.2 in Q2 2026 per HYFT's latest filing, from -$22337.7 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.9 million in Q2 2023 and bottomed at -$220510.7 in Q4 2023.
- Historically, Capital Expenditures has averaged $254259.4 across 4 years, with a median of -$50471.9 in 2025.
- Annual changes were most pronounced in 2024 — Capital Expenditures soared 167.19% — and 2025, when it sank 164.64%.
- MindWalk Holdings' Capital Expenditures stood at -$220510.7 in 2023, then surged by 78.41% to -$47598.8 in 2024, then fell by 12.07% to -$53345.0 in 2025, then surged by 1173.51% to $572662.2 in 2026.
- Business Quant data shows HYFT's Capital Expenditures at $572662.2 in Q2 2026, -$22337.7 in Q1 2026, and -$53345.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 6.26 Mn |
| 10 | MindWalk Holdings | 61.69 Mn | 53.41 Mn | 1.82 Mn | -8,024.57 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -8,024.57 |
| Jan 31, 2026 | -22,337.66 |
| Oct 31, 2025 | -53,345.05 |
| Jul 31, 2025 | -205,235.46 |
| Apr 30, 2025 | -252,279.60 |
| Jan 31, 2025 | -78,895.81 |
| Oct 31, 2024 | -47,598.77 |
| Jul 31, 2024 | -192,072.05 |
| Apr 30, 2024 | -831,185.35 |
| Jan 31, 2024 | 122,054.04 |
| Oct 31, 2023 | -220,510.67 |
| Jul 31, 2023 | -101,891.72 |
| Apr 30, 2023 | -341,440.72 |
| Jan 31, 2023 | -1.35 Mn |